Graham Kelly - Managing Director and Chief Executive Officer

Graham graduated with degrees in Science (1968) and Veterinary Science (1969) from The University of Sydney. After graduation he joined the newly-formed Department of Transplant Surgery in the Faculty of Medicine at The University of Sydney, gaining a Doctor of Philosophy in 1972. The subject of his PhD thesis was the manufacture and use of a novel drug for the treatment of tissue rejection in kidney transplant recipients, with that drug subsequently being commercialised and used globally in kidney transplantation. Graham was appointed Senior Research Fellow in Experimental Surgery at The University of Sydney, contributing through research in the areas of organ recovery for transplantation and liver transplant surgery. The increased susceptibility of organ transplant recipients to malignant cancer eventually led Graham to focus on the causes of that phenomenon, and in turn, to the broader issue of the link between diet and the incidences of certain cancers. The latter area of research led to a research interest in dietary isoflavones and their role in human health.

Graham developed a theory that dietary isoflavones were metabolised within the body into novel chemicals that possessed important hormone-like functions, and as such made important contributions to human health. That theory provided the basis for Graham leaving academia and founding the company, Norvet Ltd, which listed on the ASX in 1994. That company subsequently changed its name to Novogen Ltd and listed in the US on NASDAQ (1998). Graham was variously CEO, Executive Chairman and an Executive Director of Novogen, 1994-2006. He also was Executive Chairman of Marshall Edwards Inc (MEI) which listed on London’s AIM exchange (2001) and NASDAQ (2003). MEI subsequently became MEI Pharma Inc. Graham resigned from his executive and Board positions at Novogen and MEI in 2006.

In 2011, Graham joined private biotechnology company, Triaxial Pharmaceuticals Pty Ltd, as Executive Chairman. Concerned at the direction being taken by the Novogen Board in having stripped all assets from the Company and leaving it without a business, Graham engineered a reverse takeover of Novogen Ltd by Triaxial in December 2012 and set about rebuilding the Company. He remained as CEO and Executive Chairman of Novogen until June 2015 and was responsible for in-licensing that Company’s anti-tropomyosin drug technology, for establishing a joint venture company with Yale University, and for establishing a solid financial base.

In early-2012, Graham addressed the matter of the transport of isoflavones in the blood of humans, conducting formulation studies in a private capacity that led shortly thereafter to the concept behind NOX66. After leaving Novogen in 2015, Graham established private biotechnology company Noxopharm Pty Ltd in order to commercialise NOX66.

Ian Minns - Director, Clinical Development and Medical Affairs

Ian brings to Noxopharm over 20 years’ experience in Clinical Research and Medical Affairs covering all aspects of the clinical development process and strategic medical affairs. After graduating from the University of Sydney with a Science degree (1994) and working as a synthetic chemist at the John Curtain School of Medical Research, Ian started his career in clinical research as a research assistant at Royal North Shore Hospital, Sydney. Since then he has worked in Australia and the UK for large pharmaceutical and biopharmaceutical companies, and contract research organizations to provide expertise in clinical trial implementation and medical strategy for product commercialisation. Most recently Ian has consulted to a mid-sized biotechnology company, supporting a clinical development program across Europe, South Africa, Australia and New Zealand. With research experience which extends from phase 1 (first-in-human) through to phase 4 (post marketing) – covering the development of clinical and medical strategy, study and site feasibility, management of trials, publications, product launches, scientific training of clinical and commercial staff and development of relationships with Healthcare Professionals – and with management experience within clinical development and medical affairs, Ian will oversee the overall drug development program for Noxopharm and work with the regulatory affairs director to plan and implement strategies to meet our aim of achieving marketing approval for NOX66 as efficiently as possible.

Ron Sinani – Director, Regulatory Affairs

Ron Sinani practised as an oncology pharmacist prior to joining the pharmaceutical industry in 1992. Although his primary focus has been regulatory affairs, he has held roles involving medical affairs, pharmacovigilance, clinical research, quality assurance and health economics. Ron worked for a number of multinationals, including Sandoz (now Novartis), Abbott and Lundbeck before joining Pharmaxis in 2004 to establish its regulatory affairs capabilities and achieving marketing approval of its first product, Aridol® (in vivo diagnostic for asthma) in Australia and a number of global markets. He was also the regulatory lead for the company’s second product, Bronchitol® for the treatment of the orphan disease, cystic fibrosis. These global projects have provided Ron direct experience with overseas regulatory agencies in the US, Canada, Europe and Asia; as well as Australia. More recently, he was a regulatory strategist at Shire Pharmaceuticals where he gained insight into assessment of licensing opportunities and intellectual property protection. Ron has also consulted for the industry, first for Covance and then his own consultancy before joining Noxopharm in 2017.